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 Abstract - Mastocytosis is a heterogeneous group of 
disorders characterized by a clonal proliferation and 
accumulation of mast cells in one or more organ, primarily 
in the skin and bone marrow. The clinical spectrum of the 
disease varies from relatively benign forms with isolated skin 
lesions to very aggressive variants with extensive systemic 
involvement and poor prognosis. The growth and 
proliferation of clonal mast cells is caused by an activating 
mutation of the tyrosine kinase receptor Kit for Stem Cell 
Factor,  the main growth factor for mast cells. Clinical 
symptoms are related to mast-cell mediator release, to the 
tissue mast cell infiltration or both. The degree of infiltration 
and cell activation determines the highly variable clinical 
and morphological features. Current treatment of 
mastocytosis includes symptomatic, antimediator drugs and 





I.  INTRODUCTION 
 
 In 1869, Nettleship and Tay described the first case 
of a “rare form of urticaria that result in a brownish 
discoloration” [1]. In 1878 Paul Ehrlich first described the 
mast cells “metachromasia”, along with the tendency for 
mast cells to be associated with blood vessels, glandular 
ducts, and nerves. Further in 1949, Ellis detailed an 
autopsy report of a 1-year-old child where mast cell 
infiltration was found in numerous organs (bone marrow, 
lymph nodes, spleen and liver) [2].  
In 1957 mast cell leukemia was reported for the first 
time. In 1991 Metcalfe proposed the first classification of 
mastocytosis. In 2001 a WHO (World Health 
Organization) classification was published (Table I). The 
current WHO classification discriminates cutaneous 
mastocytosis (CM) and systemic mastocytosis (SM) [3]. 
The CM is a benign disease confined to the skin, while 
SM is a clonal hematological disease and is classified in 
indolent (ISM), aggressive (ASM) and SM with an 




II. MAST CELLS 
  
Mast cells are  an important  effectors cells of the 
immune system and  are  found  in all  vascularized tissue, 
TABLE I. CLASSIFICATION OF MASTOCYTOSIS (WHO) 
 













 Urticaria pigmentosa (UP) = 
Maculopapular CM (MPCM) 
 Diffuse CM (DCM) 








 Isolated bone marrow 
mastocytosis (BMM) 





































 Classical MCL  
 Aleukemic variant of MCL 





< 1%  
Abbreviations. SM-AML: systemic mastocytosis with acute 
myelogenous leukemia. SM-MDS: systemic mastocytosis with 
myelodysplastic syndrome. SM-MPS: systemic mastocytosis with 
myeloproliferative syndrome. SM-CEL OR SM-HES: systemic 
mastocytosis with hypereosinophilic syndrome. SM-CMML: systemic 
mastocytosis with chronic myelomonocytic leukemia. SM-NHL: 
systemic mastocytosis with non-Hodgkin lymphoma. 
 
 
especially in the skin and mucous membranes of the 
respiratory and gastrointestinal tracts. These cells release a 
variety of inflammatory mediators whose biological 
effects lead the heterogeneous symptoms in patients with 
mastocytosis [4-10]. 
Mast cells derive from CD34+ hematopoietic stem 
cells of the bone marrow and differentiate into mast cell 
precursors that are distributed via blood to tissues. 
Growth, differentiation and proliferation of mast cells are 
controlled by the tyrosine kinase receptor c-Kit (CD117) 
and its ligand stem cell factor (SCF), also of key 
importance in the development of mastocytosis. Mast cells 
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can be identified by cell surface markers FcεR1, CD13, 
CD34, CD68, and KIT (CD117) [11]. 
A wide array of proinflammatory mediators is 
secreted by mast cells after IgE-receptor cross-linking by 
allergens or other stimuli. The preformed vasoactive and 
immunoregolatory mediators, contained within mast cells 
granules, include histamine, heparine, serotonin, neutral 
proteases (tryptase, chymase, carboxypeptidase A, 
cathepsin G), major basic protein and phospholipases. 
Tryptase and chymase are the most abundant protein 
components of mast cell granules. After cell activation, 
mast cells are also able to synthesize protein and lipid 
mediators, including lipoxigenase and cyclooxygenase 
metabolites of arachidonic acid. These include 
leukotrienes (mainly LTC4), prostaglandins (mainly 
PGD2) and platelet-activating factor (PAF). Mast cells 
also produce cytokines, growth factors including IL-5, IL-
6, IL-13, IL-16, SCF, GMCSF, NGF, VEGF and various 
chemokines and possess numerous membrane-bound 
receptors [12]. 
In the bone marrow mast cells have four distinct 
morphological stages of maturation: the non-granulated 
blast cell (tryptase+), the matachromatic blast cell, the 
promastocyte (also called atypical mast cell type II), and 
the mature mast cell [13]. The stages of differentiation are 
of particular interest in that immature forms of mast cells 





III. EPIDEMIOLOGY OF MASTOCYTOSIS 
 
Mastocytosis is a rare disease. In various studies an 
incidence of 5 to 10 new cases per one million population 
per year was calculated. The prevalence (evaluated by 
epidemiologic study conducted in Europe and in United 
States) is 1/60.000. 
The most frequent variants are cutaneous and 
indolent systemic mastocytosis, the rarest is probably mast 
cell leukemia. While children almost exclusively have 
cutaneous mastocytosis forms, in adults urticaria 
pigmentosa and indolent systemic mastocytosis, is much 
more likely. In adults mastocytosis often manifests 
between age 20 and 40 years, sometimes even later. On 
the other hand, as signs and symptoms of mastocytosis are 
unspecific and overlap with many other diseases, the 
correct diagnosis may be overlooked and there is an 
unusually long latency period between the first symptoms 




IV. PATHOGENESIS OF MASTOCYTOSIS 
 
The clonal nature of mastocytosis can be established 
through the demonstration of gain-of-function mutations 
involving the tyrosin kinase domain of kit receptor in skin 
and/or bone marrow cells. KIT (CD117) is a type III 
tyrosine kinase (TK) receptor that is characterized by an 
extracellular domain with five immunoglobulin-like loops, 
a transmembrane domain, an juxtamembrane 
autoinhibitory domain and a TK domain. The first three 
immunoglobulin (Ig)-like loops of the extracellular 
domain form the binding site for stem cell factor (SCF) or 
KIT ligand, while the fourth and fifth loops play a role in 
stabilizing the SCF-induced KIT dimer. The 
autoinhibitory juxtamembrane domain is essential for the 
downregulation of tyrosine phosporylation. The kinase 
portion of KIT is composed of two domains which are 
separated by a kinase insert: the TK1 domain is 
constituted by the small N-terminal lobe that expands 
from amino acids 582–684 and contains the ATP binding 
site, and the TK2 domain is formed by the large C-
terminal lobe containing the phosphotransferase site and 
the activation loop (amino acids: 810–839). The 
interaction between KIT and its ligand, SCF, plays a key 
role in regulating mast cell proliferation, maturation, 
adhesion, chemotaxis, and survival. 
In over 90 % of adults with mastocytosis the somatic 
activating kit point mutation on exon 17 at codon 816 
(substitution of aspartate by valine in the tyrosine kinase 
domain of the kit receptor or Asp-816-Val or kitD816V) 
can be detected. This mutation leads to 
autophosphorylation of the receptor resulting in 
endogenous-autonomous mast cell proliferation [14-18]. 
However, have been reported other forms of kit mutations, 
not only on exon 17: these mutations affect several 
different domains of the receptor, such as the extracellular 
domain, transmembrane domain, juxtamembrane domain 
and activation loop domain [19]. In children mutagenesis 
is much less homogeneous as in adults. In a recent study, 
Bodemer et al. analyzed cutaneous biopsies of 50 children 
with mastocytosis (aged 0-16 years): the kit mutation at 
codon 816 on exon 17 was detected in 42 % of cases, 
while in 44% in of cases mutations were observed in the 
extracellular domain of kit on exon 8 and 9 [20]. All 
mutations were somatic and led to kit activation. 
Other oncogenic mutations recently identified in 
mastocytosis patients include TET2 (TET oncogene 
family member 2) and N-RAS [21]. These mutation are 
not specific of mastocytosis and their pathogenetic role 
and/or prognostic impact is currently uncertain. TET2 is a 
putative tumor suppressor gene. In one study, the 
frequency of TET2 mutations in SM was 29% and its 
presence was associated with monocytosis. Further, TET2 
mutations cosegregated with KITD816V but did not 




V. CLASSIFICATION OF MASTOCYTOSIS 
 
Mastocytosis is a rare disease characterized by a 
clonal proliferation of morphologically and 
immunophenotypically abnormal mast cells, that 
accumulate in one or more organ systems (skin, bone 
marrow, lymph node, gastrointestinal tracts, liver, spleen, 
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etc.) [1-8]. The clinical presentation of mastocytosis is 
heterogeneous, ranging from skin-limited disease 
(cutaneous mastocytosis, CM), particularly in childhood 
with spontaneous regression of skin lesions before 
adolescence [22] to more aggressive forms in adult 
patients with extracutaneous involvement (systemic 
mastocytosis, SM) that maybe associated with multiorgan 
failure [23].  
 
Cutaneous mastocytosis 
The most common clinical sign of mastocytosis 
(both cutaneous and systemic disease) is the presence of 
typical skin lesions of urticaria pigmentosa, which appear 
as fixed, dark red-brown macules or papules. These 
lesions exhibit Darier’s sign that is considered 
pathognomonic of mastocytosis and it consists in urticarial 
swelling induced by scratching of skin lesions [24-26]. 
Cutaneous mastocytosis is defined as an accumulation of 
mast cells limited to the skin. Clinically, various subtypes 
are described: urticaria pigmentosa, diffuse CM, and 
mastocytoma of the skin. 
- Maculopapular cutaneous mastocytosis/Urticaria 
pigmentosa (MPCM/UP) is the most common variant of 
CM, that it manifests as 0,5- 1 cm yellowish tan to red-
brown macules or slightly raised papules (Figure 1). The 
affected areas include the trunk and extremities, while the 
face, scalp, palms, and soles tend to be free of lesions.  
 
 
Figure 1. Urticaria Pigmentosa 
 
Much rarer are the bullous variant (often in the first weeks 
of life), the plaque form, the nodular form and the 
Teleangectasia macularis-eruptiva perstans (TMEP) with 
multiple hyperpigmented maculae as well as erythema 
with telangiectases. This form is associated with either 
SM or with various hematological abnormalities, such as 
myelodysplasia, myeloproliferative disorders, acute 
myeloid leukaemia, and lymphoproliferative disease [27]. 
These variants do not constitute independent forms in the 
WHO classification. 
- Diffuse cutaneous mastocytosis (DCM) can involve 
extensive areas of the skin. It is a rare (1-3% of the cases 
of CM) severe variant of CM, that occurs predominantly 
in children. DCM can appear at birth (congenital and 
neonatal) or in early infancy. Blistering and bullae may be 
the presenting symptoms and the blisters can be 
hemorrhagic. The skin may be leathery and thickened. 
Hyperpigmentation may persist into adulthood and 
dermographism may be prominent. 
- Mastocytoma of skin is a single lesion of the skin, 
appearing as yellowish to reddish nodular lesions, in part 
with blistering. It manifests predominantly in childhood 
and in most cases heals spontaneously (Fig. 2). 
Cutaneous mastocytosis has a highly favorable clinical 
prognosis. The majority of children with CM show a good 
prognosis with gradual resolution of both symptoms and 
skin lesions [28]. 
 
Systemic mastocytosis 
Systemic Mastocytosis is highly heterogeneous 
diseases with by definition involvement of at least one 
extracutaneous tissue (skin involvement is frequent but 
not obligatory). Since the bone marrow is almost always 
involved, bone marrow biopsy is the method of choice to 
confirm the diagnosis of systemic mastocytosis. Patients 
with systemic mastocytosis have mediator related 
symptoms and/or signs and symptoms caused by mast 
cells infiltration [3,5]. Organ infiltration by MC may lead 
not only to organomegaly, but also to impairment or even 
loss of organ function and in severe (high grade) disease, 
bone marrow failure with anemia, thrombocytopenia, 
and/or recurrent infections (due to neutropenia) may 
occur. Typical clinical findings (B and C-findings) were 
established by WHO to determinate the type of systemic 
mastocytosis (Table II). B-findings referred to organ 
involvement without organ failure, while C-findings 
referred to organ involvement with organ dysfunction. 
The presence of a C- finding is sufficient to diagnose 
advanced SM and the patient is a candidate for 
chemotherapy. 
 
Variants and sub-variants  of systemic mastocytosis 
- Indolent systemic mastocytosis (ISM). ISM is the most 
common form of SM, accounting for about two thirds of 
all cases. Commonly, ISM involves both the skin and 
bone marrow, with urticaria pigmentosa seen in more than 
90% of cases. Usually ISM manifests in adulthood. Bone 
marrow is affected in almost 100% of cases and usually 
contains multifocal mast cell infiltrates, but there are not 
associated hematologic disorders or organ dysfunction. In 
ISM “C findings” are not found; if “C findings” are 
present, the disease has progressed to ASM.  
Two subvariants of ISM are Isolated Bone Marrow 
Mastocytosis (BMM) and Smoldering Systemic 
Mastocytosis (SSM). In the BMM the mast cell infiltration 
is only found in bone marrow, but not in the skin. The rare 
smoldering SM is differentiated from the more common 
indolent variety by massive mast cell proliferation and 
tryptase levels over 200 μg/l. Even in smoldering SM no 
signs of bone marrow insufficiency should be detectable 
(important differentiation from aggressive SM).  
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- Systemic mastocytosis with an associated clonal 
hematological non-mast cell disease (SM-AHNMD). 
Systemic mastocytosis with an associated clonal 
hematological non-mast cell disease (SM-AHNMD) is the 
second most frequent subtype of systemic mastocytosis, 
comprising one fourth to one third of the cases of SM. SM 
and AHNMD are usually diagnosed simultaneously in 
bone marrow biopsy. All subtypes of hematologic 
neoplasia have been reported within the context of SM-
AHNMD. Myeloid disorders comprise 80-90% of the 
AHNMDs, while lymphoid disorders comprise the other 
10-20 %. The prognosis of SM-AHNMD usually depends 
on the AHNMD and not on SM [29]. 
- Aggressive systemic mastocytosis (ASM). Aggressive 
systemic mastocytosis is a rare form (represents only 
about 5% of all patients with SM), characterized by the 
extensive infiltration of tissue depending on the involved 
organ leads to highly different symptoms as a result of 
dysfunction with signs of insufficiency being considered 
as C-findings in the WHO criteria. These C-findings 
different clinical sign of organ dysfunction: hepatopathy 
with hypoproteinemia, ascites, pleural and/or pericardical 
effusion, prolongation of prothrombin time, and bleeding 
disorders; bone fractures; severe cytopenia and 
malabsorption. A subvariant of ASM is 




TABLE II – B-FINDINGS AND C-FINDINGS 
 
B-findings* C-findings** 
Impairment of organ function 
Progressive C-findings 
1. Elevated grade of mast cells infiltration 
 
Infiltration grade of mast cells in the bone 
marrow >30%  
 





Hypercellular marrow with signs of 
myelodysplasia or myeloproliferation, but blood 






Hepatomegaly without ascites or signs of 
impairment of organ functions, and/or 














 Absolute neutrophil count 
< 1000/μL 
 Hemoglobin < 10 g/dl 
 Platelets < 100.000/ μL 
 
(one or more of these) 
 
 
2. Organopathy (liver): 
 
Hepatomegaly (palpable) with ascites, elevated 





3. Organopathy (spleen): 
 
Splenomegaly with hypersplenism 
 
 
4. Organopathy (GI tract): 
 




5. Organopathy (skeleton): 
 












1. Severe pancytopenias: 
 
 Absolute neutrophil count 
< 500/μL + recurrent infections 
 Need for transfusions 





2.  Progressive impairment of liver 
functions, liver failure (coma), loss of 





















* When two or three B-findings are recorded, the final diagnosis is SM smouldering 
**Organ failure caused by infiltration of neoplastic mast cells: a single C-findings is sufficient to diagnose ASM 
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Eosinophilia, definited by a increased of number of 
eosinophil (>1500/mm
3 
). In this particular form the FIP1-
like-1 (FIPL1)/platelet-derivated growth factor receptor 
alpha (PDGFRα) fusion gene is often detected and it is 
responsive to the tyrosine kinase inhibitor, imatinib 
mesylate [6]. In patients with ASM the serum tryptase 
level is usually over 200 μg/l. The prognosis of ASM is 
poor. 
- Mast cell Leukemia. Mast cell leukemia (MCL) is 
characterized by leukemic infiltration of organs by 
immature or atypical neoplastic mast cells. Typically, 
mast cells are more than 10% of the circulating blood 
cells. MCL is rare and has a poor prognosis. A subvariant 
of MCL, aleukemic MCL, has less than 10% immature of 
atypical mast cells within circulating blood cells. Over the 
course of the disease, patients may progress from 
aleukemic MCL to MCL [30]. 
 
 




VI. MEDIATOR-RELATED SYMPTOMS IN 
MASTOCYTOSIS 
 
In both CM and SM the clinical picture is often 
dominated by local and systemic symptoms generated by 
the acute or chronic release of mast cell-derived 
mediators. These clinical signs and symptoms are highly 
variable inter- and intra-individually. These symptoms 
depend on the release of mediators, such as histamine, 
heparin, tryptase, leukotrienes and cytokines. Related 
clinical findings are often unspecific symptoms: headache 
attacks, fatigue, pruritus, flushing, often in combination 
with hypotensive crises, syncope and tachycardia, 
gastrointestinal complaints (nausea, abdominal pain, 
diarrhea, vomiting, gastritis, peptic ulcers), bone pain and 
rarely even neurologic-psychiatric symptoms. Such 
symptoms can occur in all patients with mastocytosis, but 
in patients with SM these symptoms are often recurrent, 
severe and require continuous medical treatment. Almost 
all patients report variable worsening of symptoms after 
intensive physical activity, consumption of alcohol, 
infections, nonsteroidal anti-inflammatory drugs but also 
during emotional stress.  
In cutaneous mastocytosis flushing, pruritus, 
erythema and swelling are frequent signs and symptoms 
and they may occur spontaneously or be induced by 
specific triggers. The intensity of skin involvement can be 
variable. In majority of patients the typical maculae and 
plaques develop primarily on the trunk and limbs; the 
head, palms and soles are usually spared. In children, in 
contrast, typically the head and lateral face are involved. 
Gastrointestinal symptoms can be prominent in patients 
with mastocytosis and these symptoms can be caused by 
mast cell proinflammatory mediators and/or mast cell 
organ infiltration. The mediator related symptoms are 
diarrhea, abdominal pain, peptic ulcer disease and 
gastrointestinal bleeding; while in ASM patients mast cell 
tissue infiltration caused severe malabsorption, chronic 
diarrhea, weight loss, organomegaly (spleen, liver) with 
dysfunction, ascites due to periportal fibrosis up to hepatic 
failure. 
Patients can also develop osteopenia or osteoporosis 
with bone pain and possible pathologic fractures. 
Pathologic fractures are considered a marker of advanced 
mastocytosis specially when they are associated with high 
levels of serum tryptase; while osteoporosis usually 
depend on the intensity of mast cell mediator release. 
Indeed, heparin, tryptase and IL-6 can be activated in vitro 
RANK-L (receptor activator of nuclear factor-kB ligand) 
[31]. 
Patients with mastocytosis have an increased risk of 
anaphylaxis. In adults with mastocytosis, the cumulative 
prevalence of anaphylaxis has been reported to be 22% to 
50%, and in children 6% to 10% [32]. Anaphylactic 
reactions have been reported in all forms of mastocytosis, 
but patients with systemic disease have an increased risk 
of anaphylaxis as compared with patients with only 
cutaneous disease. The most frequently reported elicitor of 
anaphylaxis is hymenoptera venom (wasp stings) [33]. 
Other factors that caused anaphylaxis are some drugs 
(opiates, including morphine and codeine), food, 
radiological contrast media containing ionic iodine and 
substances administered during general anesthesia (e. g. 
muscle relaxants). These factors can be activate mast cells 




VII. DIAGNOSIS OF MASTOCYTOSIS 
 
The diagnosis of cutaneous mastocytosis can usually 
be made based on history and clinical criteria with careful 
skin inspection. The diagnosis is based on the 
demonstration of characteristic skin lesions (major 
criterion) and on the presence of one minor or two minor 
criteria: a) demonstrate on the skin biopsy of (multifocal 
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or diffuse) aggregates of mast cells in the papillary dermis 
extending into the reticular dermis; b) presence of D816V 
mutations. The Darier sign with urticarial swelling after 
mechanical rubbing of macules or papules is almost 
always positive. Inspection of the skin is supplemental by 
palpation of peripheral lymph node stations and 
abdominal organs. In children bone marrow study is 
recommended only if there is suspicion of progression of 
disease: in case of organomegaly or significant 
lymphadenopathy, abnormalities on peripheral blood 
counts, elevated serum tryptase levels, severe recurrent 
systemic mast cell mediator-related symptoms or 
persistence of skin lesions after puberty. 
For the diagnosis of systemic mastocytosis should be 
fulfilled the WHO criteria proposed in 2001 (Table III). 
These consist of one major and four minor criteria. In 
order to satisfy the diagnosis of systemic mastocytosis, 
either one major criterion and one minor criterion or at 
least three minor criteria should be present.  
 
 
TABLE III – WORLD HEALTH ORGANIZATION 







Multifocal dense infiltrates of mast 
cells (tryptase positive) in bone 
marrow and/or other extracutaneous 






a. More than 25% of the mast cells 
in bone marrow smears or tissue 
biopsy sections are spindle shaped 
or display atypical morphology 
 
b. Detection of a c-kit point 
mutation in codon 816 in blood, 
bone marrow, or other lesional 
tissue 
 
c. Evidence of CD2 and/or CD25 on 
mast cells in bone marrow, blood, 
or extracutaneous tissue 
 
d. Serum tryptase more than 20 
ng/ml (not applicable in SM-
AHNMD) 
 
* One major and one minor, or three minor criteria are needed for the 
diagnosis of systemic mastocytosis 
 
 
The WHO major criterion as well as 2 of 4 WHO 
minor criteria are morphological criteria, so that both 
careful collection of samples (especially bone marrow 
biopsy and aspirates) as well as sufficient experience in 
the histo- and molecular pathological evaluation of the 
material are essential for making the diagnosis. The 
recommended method of evaluation of mast cells in bone 
marrow biopsy is immunohistochemical staining with 
tryptase. Neoplastic mast cell generally express CD25 
and/or CD2, and the abnormal expression of at least one 
of these two antigens counts as a minor criterion toward 
the diagnosis of SM [34]. Recently, CD30 was detected in 
mast cells in aggressive (advanced) systemic 
mastocytosis. Specifically, it has been described that 
CD30 is preferentially expressed in the cytoplasm of 
neoplastic mast cells in ASM and MCL, but not in ISM. 
Notably, strong expression of CD30 in the cytoplasm of 
most neoplastic mast cells is in favor of the diagnosis 
ASM or MCL. Thus, CD30 may be a forthcoming 
gradingand prognostic marker in systemic mastocytosis 
[35, 36].  
The determination of serum tryptase levels (normal 
value under 11.4 μg/l) is in principle a good diagnostic 
and differential diagnostic parameter, also in evaluation of 
the disease course. The level correlates with the mast cell 
proliferation  and its activation [37-39]. Elevated serum 
tryptase levels are therefore not pathognomonic for SM, as 
elevated levels can be detected also in patients with acute 
(40 % of patients have elevated levels) or chronic myeloid 
leukemia and more rarely also in myelodysplastic 
disorders. In patients with elevated tryptase levels after 
questionable anaphylactic reactions, determining the 
course after 4 to 8 weeks is recommended for a 
differential diagnosis of SM. When SM is suspected and 
serum tryptase is elevated, bone marrow biopsy should 
always be performed. Even with only slightly elevated 
tryptase levels and unclear complaints, bone marrow 
biopsy is recommended. 
SM without skin involvement is rare and is then also 
often difficult to recognize. In face of the often diffuse 
complaints of patients many diseases must be included in 
the differential diagnosis. Patients who present a severe 
anaphylactic reaction, e. g. after an insect sting – even 
without the detection of specific IgE – or who develop an 
unclear (idiopathic) anaphylactic reaction are 
diagnostically problematic. Here in every case further 
mastocytosis diagnostics should be performed. A lack of 
skin involvement is more often associated with aggressive 
forms (ASM, mast cell leukemia). Extremely rare and 
therefore difficult to diagnose routinely are mast cell 
sarcoma, mastocytosis of the spleen and benign 
extracutaneous mastocytoma. 
A careful internal medicine work-up is always 
recommendable. Organ-related symptoms e. g. of the 
gastrointestinal tract result in specific diagnostics (e. g. 
endoscopy with step-by-step biopsies and mast cell-
specific immunohistochemical and molecular pathological 
processing). Differentiation between symptoms due to 
mast cell infiltrates and symptoms due to massive 
mediator release can be problematic in the individual case. 
With strict observation of the major and minor criteria and 
a standardized step-by-step diagnostic approach 
mastocytosis can almost always be clearly identified and 
subtyped [8]. In ISM with a stable course only annual 
laboratory controls (routine serology, differential blood 
count, serum tryptase) and more invasive studies only in 
case of clinical/ laboratory chemical alterations are 
recommended. 
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VIII. PROGNOSIS OF MASTOCYTOSIS 
 
The variants and subvariants of mastocytosis, with 
their wide range of clinical manifestations, have relatively 
defined prognosis. Most forms of CM in children 
spontaneously remit by puberty [40]. The prognosis of 
patients with mastocytosis depends on the degree of organ 
infiltration by mast cells, the evolution of associated 
hematologic disorders, the occurrence of anaphylaxis and 
the associated osteoporosis with pathological fractures. In 
adults, the prognosis of indolent systemic mastocytosis is 
generally good and these patients usually have a normal 
life expectancy; while advanced systemic mastocytosis 
and mast cell leukemia are associated with a severe 
prognosis. 
Several different clinical, sierological, 
cytomorphological and immunological variables have 
been described as a prognostic findings in SM. Clinical 
prognostic variables include absence of skin lesions, large 
osteolyses, weight loss, malabsorption, enlarged liver with 
portal hypertension and splenomegaly with hypersplenism 
[41]. The absence of a skin lesion is typical for an 
aggressive disease variant. Low levels of albumin can be 
caused by hepatopathy or malabsorption. Hepatomegaly 
with elevated liver enzymes and/or signs of portal 
hypertension (such as ascites) is indicative for progressive 
destruction of the liver by MC infiltrates. Both progressive 
hepathopathy and malabsorption are markers of poor 
prognosis in SM. 
In patients with indolent systemic mastocytosis, the 
β2-microglobulin level is a prognostic marker predicting 
an unfavorable outcome [42]. SM with eosinophilia was 
found to be predictive for a significantly reduced overall 
and event-free survival compared with patients without 
eosinophilia [41]. 
Another prognostic factor in patients with 
mastocytosis is the percentage of mast cells in the bone 
marrow smear. The majority of patients with ISM present 
with ≤ 5% MCs in bone marrow smear. Patients with a 
percentage of MCs in the bone marrow smear greater than 
5%: have a lower survival [43]. 
As previously mentioned, CD30 is preferentially 
expressed on neoplastic MCs in ASM and MCL, but not 
ISM. The strong expression of CD30 in the cytoplasm of 





IX. TREATMENT OF MASTOCYTOSIS 
 
Recently, a number of therapeutic approaches for the 
treatment of mastocytosis have been reported [46]. 
Management of patients within all categories of 
mastocytosis includes:1) a careful counseling of patients 
and care providers; 2) avoidance of factors triggering 
acute mediator release; 3) treatment of acute mast cell 
mediator release; 4) treatment of chronic mast cell 
mediator release, and if indicated; 5) an attempt to treat 
organ infiltration by mast cells. 
Complete information about the disease, including 
guide-lines for avoidance of triggering factor, and risks 
associated with massive mast cell mediator release may be 
given to the patients and/or their parents in case of 
children. The first arm of therapy is to avoid mast cell 
degranulation. Triggering factors are various: physical 
stimuli (heat, cold, friction of skin lesions, pressure, 
excessive sunlight); emotional factors (stress, anxiety, 
sleep deprivation); infection disease with fever; drugs 
(aspirin and other non steroidal anti-inflammatory drugs, 
morphine and derivatives, polymyxin-B, amphotericin B). 
Skin lesions represent a problem in many patients. A 
treatment for skin lesions is oral psoralen plus UV-A 
(PUVA). In response to PUVA, most patients show a 
substantial regression of skin lesions. However, due to the 
limited duration of responses, long-term treatment with 
repeated cycles of PUVA is necessary [47]. 
The primary objective of all clinical forms of 
mastocytosis (both cutaneous and systemic mastocytosis) 
is the treatment of mediator-related symptoms. Non 
sedating histamine H1 receptor antagonists (rupatadine, 
levocetirizine and desloratadine) have been shown to be 
useful in the treatment of flushing, pruritus, wheals, 
swelling and the sensation of burning of the skin. 
Additional administration of histamine H2 receptor 
antagonists, such as ranitidine is suggested in cases where 
H1-receptor antagonists monotherapy is inadequate. 
Corticosteroids, administered over a short period of time, 
may be considered in case of recurrent and severe 
mediator-related symptoms. 
Patients with gastrointestinal complaints such as 
pain, vomiting, diarrhea or meteorism profit from therapy 
with chromolyn sodium, antacids, proton pump inhibitors 
and H1 receptor antagonists and depending on the degree 
of indirect histamine release-induced symptoms also with 
combinations of H1 and H2 receptor antagonists. 
Adults with mastocytosis and children with extensive 
cutaneous involvement are at increased risk of 
anaphylaxis and should carry an emergency kit for self-
medication that includes epinephrine and, as warranted, 
antihistamine and corticosteroids. Treatment with 
omalizumab (anti- IgE) can be successful in selected 
patients with otherwise uncontrolled idiopathic 
anaphylaxis and in those with anaphylaxis during the 
initiation of specific immunotherapy [48]. 
Due to the increased perioperative risk, patients, 
anesthesiologists and surgeons should discuss 
comprehensively the procedure to lower the risk of 
anaphylaxis. As premedication antihistamines and 
corticosteroids in a sufficiently high dosage should be 
selected. Only selected drugs that are proven not to be 
relevant histamine releasers and do not provoke mast cell 
activation should be administered perioperatively.  
In patients with advanced systemic mastocytosis 
(with the presence of “C-findings”) the prime goal is to 
inhibit further mast cell proliferation with cell infiltration 
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and cell activation. In cases of SM-AHNMD the 
hematologic disorder must be treated. 
Interferon (IFN)-α is considerate the first-line 
cytoreductive therapy in aggressive systemic 
mastocytosis. Prednisone (30-60 mg/day) is commonly 
added at the start of treatment to improve tolerability and 
response. Several studies have shown IFN-α to improve 
symptoms of MC degranulation, decrease bone marrow 
MC infiltration, and reduce mastocytosis-related 
ascites/hepatosplenomegaly, cytopenia, skin lesions and 
osteoporosis. The frequency of major response (complete 
resolution of one or more baseline C findings) is 
approximately of 50%. IFN-α treatment is frequently 
complicated by toxicities, including flu-like symptoms, 
bone pain, fever, cytopenia, depression and 
hypothyroidism. 
Cladribine or 2-chlorodeoxyadenosine (2-CdA) has 
activity in all SM subtypes. 2-CdA can be used in patients 
who are refractory or intolerant to IFN-α. A reduction of 
the mast cell load could be demonstrated, but controlled 
studies are urgently needed. Potential toxicities of 2-CdA 
include myelosuppression and lymphopenia with 
increased risk of opportunistic infections. 
In recent years various tyrosine kinase (TK) 
inhibitors have also been employed for SM. Imatinib 
mesilate (IM) inhibits a series of receptor TK including 
kit, abl, bcr-abl, platelet-derived growth factor receptor. 
Due to steric interaction of the kitD816V mutation at the 
receptor imatinib is effective only in patients with SM 
lacking this mutation. Indeed it demonstrates in vitro 
efficacy against wild-type KIT and certain transmembrane 
(F522C) and juxta-membrane (V560G) KIT mutants, but 
not the common kinase (D816V) domain mutants. 
Furthermore, imatinib showed efficacy in patients with 
one of subvariant of ASM, lymphadenophatic systemic 
mastocytosis with eosinophilia: this particular subset has a 
FIP1-like-1(FIPL1)/platelet-derivated growth factor 
receptor alpha (PDGFRα) fusion gene defect. 
New tyrosine kinase inhibitors under clinical 
investigation for blocking KIT are dasatinib, nilotinib, 
masatinib mesilate and PKC412 (midostaurine). However, 
it is currently not clear which patients with SM will 
benefit from such treatments and more studies are needed 
to clarify the advantage of tyrosine kinase inhibitors over 
IFN-α or cladribine, which are currently considered first 
line treatment in ASM [41,50]. A possible treatment 
option in the future is the combination of multiple 
cytoreductive drugs with potential synergistic effects. 
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